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Background: Despite bronchiectasis being increasingly recognised as an important cause of chronic respiratory
morbidity in both indigenous and non-indigenous settings globally, high quality evidence to inform management
is scarce. It is assumed that antibiotics are efficacious for all bronchiectasis exacerbations, but not all practitioners
agree. Inadequately treated exacerbations may risk lung function deterioration. Our study tests the hypothesis that
both oral azithromycin and amoxicillin-clavulanic acid are superior to placebo at improving resolution rates of
respiratory exacerbations by day 14 in children with bronchiectasis unrelated to cystic fibrosis.
Methods: We are conducting a bronchiectasis exacerbation study (BEST), which is a multicentre, randomised, double-
blind, double-dummy, placebo-controlled, parallel group trial, in five centres (Brisbane, Perth, Darwin, Melbourne,
Auckland). In the component of BEST presented here, 189 children fulfilling inclusion criteria are randomised
(allocation-concealed) to receive amoxicillin-clavulanic acid (22.5 mg/kg twice daily) with placebo-azithromycin;
azithromycin (5 mg/kg daily) with placebo-amoxicillin-clavulanic acid; or placebo-azithromycin with placebo-
amoxicillin-clavulanic acid for 14 days. Clinical data and a paediatric cough-specific quality of life score are obtained at
baseline, at the start and resolution of exacerbations, and at day 14. In most children, blood and deep nasal swabs are
also collected at the same time points. The primary outcome is the proportion of children whose exacerbations have
resolved at day 14. The main secondary outcome is the paediatric cough-specific quality of life score. Other outcomes
are time to next exacerbation; requirement for hospitalisation; duration of exacerbation; and spirometry data.
Descriptive viral and bacteriological data from nasal samples and blood markers will also be reported.
Discussion: Effective, evidence-based management of exacerbations in people with bronchiectasis is clinically
important. Yet, there are few randomised controlled trials (RCTs) in the neglected area of non-cystic fibrosis
bronchiectasis. Indeed, no published RCTs addressing the treatment of bronchiectasis exacerbations in children exist.
Our multicentre, double-blind RCT is designed to determine if azithromycin and amoxicillin-clavulanic acid, compared
with placebo, improve symptom resolution on day 14 in children with acute respiratory exacerbations. Our planned
assessment of the predictors of antibiotic response, the role of antibiotic-resistant respiratory pathogens, and whether
early treatment with antibiotics affects duration and time to the next exacerbation, are also all novel.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR) number ACTRN12612000011886.
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Compared to the early 20th century, the prevalence of
bronchiectasis has fallen substantially. Although regarded
as an ‘orphan disease’ in affluent countries, reports of
prevalence of bronchiectasis are increasing [1,2]. Bronchi-
ectasis remains a major contributor to chronic respiratory
morbidity [2,3] and mortality [1,4] in both Indigenous [5]
and non-Indigenous populations [6]. In our recently com-
pleted multicentre study of children newly referred for
chronic cough and managed in accordance to a standar-
dised protocol [7], 31 (9%) of the 346 children had bron-
chiectasis proven on radiology [8]. In the Northern
Territory in Australia, the incidence of bronchiectasis in
the first year of life is 118 in 100,000 [9]. The estimated
prevalence of bronchiectasis is 1,470 per 100,000 in
Central Australian Indigenous children aged below
15 years [10] and 1,600 per 100,000 in Alaskan Native
children [11]. In the United States, reported prevalence in
adults range from 4.2 to 271.8 per 100,000 [6]. However,
any reported prevalence is likely to be an underestimate as
many cases are misdiagnosed or coexist with other dis-
eases like asthma [12-14] and chronic obstructive pulmon-
ary disease (COPD) [15]. Even without accounting for
these unrecognised cases, globally there are far more
patients with bronchiectasis than cystic fibrosis (CF),
which has a prevalence of 7.4 to 7.9 per 100,000 in the
European Union and the United States [14].
Effective clinical management reduces both short- and
long-term morbidity (and likely mortality) associated with
bronchiectasis [16-18]. There is increasing evidence that
intensive treatment of children who either have bronchiec-
tasis or are at risk of developing severe bronchiectasis pre-
vents poor lung function in adulthood [17-20]. Cohort
data have shown that approximately 80% of newly diag-
nosed adults (non-smokers) with bronchiectasis reported
symptoms dating back to childhood and that the duration
of chronic cough (the most common symptom of bronchi-
ectasis [21]) was related (r =−0.51, P<0.001) to lung func-
tion at diagnosis [22]. Arguably, appropriate overall
management and treatment of exacerbations (leading to
reduction of persistent symptoms) potentially prevents or
reduces deterioration of chronic respiratory disease [23].
Determinants of accelerated lung function decline in
adults with bronchiectasis are the frequency of hospita-
lised exacerbations, increased systemic inflammatory mar-
kers and Pseudomonas aeruginosa infection [24]. Amongst
other factors, increased mortality risk is associated with
the degree of lung function impairment [25]. No prospect-
ive data exist in children. Our study and a London-based
retrospective study found that, with appropriate treatment
in specialised centres, lung function improves and can be
maintained [18,20]. However, those with poor lung func-
tion at diagnosis, although substantially improved, were
likely to still have poor lung function five years later [20].We also found that the only significant predictor of a de-
cline in forced expiratory volume in one second (FEV1)
was frequency of hospitalised exacerbations [20]. Forced
expiratory volume in one second (FEV1)% predicted
decreased by 1.95% with each previous hospitalised ex-
acerbation [20]. As airway injury in children is superim-
posed upon the physiological changes involving lung
growth and development [26,27], improvement in child-
hood bronchiectasis may impact favourably upon future
adult lung function. Early and effective management of
bronchiectasis exacerbations in children may lead to
reduced hospitalisations, better quality of life (QOL) and
improved future adult lung function.
Antibiotics are one of the key interventions used to
treat acute respiratory exacerbations of bronchiectasis
[21,28]. However, it is biologically plausible that antibio-
tics are not useful for treating some respiratory exacer-
bations triggered by viral infections. Our retrospective
study found that 34% of exacerbations were preceded by
a viral-like illness [29]. While most respiratory physi-
cians will treat exacerbations intensively (with antibiotics
and airway clearance), other doctors do not. Those
choosing not to use antibiotics routinely argue that most
episodes of exacerbations and cough are caused by viral
infections and hence do not require antibiotic therapy.
This may be appropriate but viral-bacterial interactions
in the airways risk prolonged endobronchial bacterial in-
fection that, with the associated inflammatory cascade,
may cause further lung injury [23,30]. Better evidence to
guide the management of exacerbations in people with
bronchiectasis is needed.
Aims of the study
There are two components of BEST; here we present the
study protocol of the first phase (BEST-1). The second
phase of BEST (BEST-2) will address the question “Is
daily azithromycin non-inferior (within 20% margin) to
amoxicillin-clavulanic acid in achieving resolution of
exacerbations on day 21?” The protocol for BEST-2 will
be the subject of a later paper.
This first phase of our proposed national multicentre
double-blind double-dummy randomised controlled trial
(RCT) is designed to answer our primary questions, as fol-
lows. Amongst children with non-CF bronchiectasis, does
azithromycin improve the resolution of respiratory exacer-
bations by day 14 compared with placebo, and does
amoxicillin-clavulanic acid improve the resolution of re-
spiratory exacerbations by day 14 compared with placebo?
Our secondary aims are to:
1. determine the effect of azithromycin or amoxicillin-
clavulanic acid on the QOL, systemic inflammation,
time to next respiratory exacerbation, and duration
of exacerbations;
Chang et al. Trials 2012, 13:156 Page 3 of 9
http://www.trialsjournal.com/content/13/1/1562. explore factors that predict response to antibiotics,
including respiratory pathogens (viruses, bacteria,
macrolide-resistant bacteria) present in respiratory
secretions and blood markers; and
3. describe the point prevalence and diversity of
respiratory viruses, Mycoplasma pneumoniae and
Chlamydia species during exacerbations using
sensitive molecular detection techniques.
Our study tests the primary hypothesis that both oral
azithromycin and amoxicillin-clavulanic acid are superior
to placebo in improving the resolution rate of respiratory
exacerbations by day 14 in children with non-CF
bronchiectasis.
Methods/Design
Study design
We are conducting a multicentre, parallel group, double-blind
placebo RCT (with concealed allocation) to assess the impact of
treatment with antibiotics (azithromycin or amoxicillin-
clavulanic acid) in children with an exacerbation of
bronchiectasis. Our study plan is summarised in
Figure 1.
Eligibility
The inclusion criteria are age below 18 years at time of
study enrolment; diagnosed with bronchiectasis by a re-
spiratory physician following high resolution computed
tomography in the five years immediately prior to study
entry or, if diagnosed earlier, have been followed regularly
by a respiratory physician for treatment of bronchiectasis;
and has experienced two or more respiratory exacerbations
in the 18 months prior to study entry.
Exclusion criteria are current severe exacerbation of
bronchiectasis (dyspnoea, hypoxia or hospitalisation), re-
cent (in last 8 weeks) in the entry; CF; liver dysfunction;Figure 1 Overall schematic study design. Amox-clav: amoxicillin-
clavulanic acid; azithro: azithromycin.allergy or sensitivity to penicillin or macrolides; current
or recent lower airway infection by a member of the
Pseudomonas genus group of Gram-negative bacteria (in
the four months prior to study enrolment); has received
antibiotics belonging to the macrolide or penicillin class
of antibiotics within three weeks immediately prior to
study entry; or is currently receiving oncological
treatment.
Recruitment
Eligible children will be identified from clinics in our cen-
tres (Brisbane, Perth, Darwin and Melbourne in Australia
and Auckland in New Zealand). Parents will be approached
and informed consent obtained. Baseline pre-exacerbation
data will be collected (Figure 1), parents contacted monthly
and children reviewed every three months. Parents will be
educated specifically on symptoms of exacerbations and
asked to contact the research nurse at the onset of an
exacerbation.
Intervention and follow-up
A double-dummy design is planned. If eligibility is ful-
filled and after informed consent has been obtained, the
child is randomised to one of three arms. At the start of
the exacerbation, the child will receive amoxicillin-
clavulanic acid with placebo-azithromycin, azithromycin
with placebo-amoxicillin-clavulanic acid or placebo-
azithromycin with placebo-amoxicillin-clavulanic acid.
Amoxicillin-clavulanic acid dose is 22.5 mg/kg/dose (up
to 40 kg) twice a day (max 900 mg/dose). Azithromycin
dose is 5 mg/kg/day, max of 200 mg daily. Equivalent
volumes in placebo will be given in all arms. All treat-
ments will continue for 14 days.
An exacerbation is defined as an increase in sputum
volume or purulence, or three or more days of change in
cough (> 20% increase in cough score [31] or type (dry
to wet) [32]). We validated this definition in our pro-
spective study and found that the kappa values (between
clinicians) of these symptoms and signs were excellent
(> 0.75) [33]. Daily diaries will also be collected during
exacerbations until the scores for two or more days re-
flect the child’s ‘baseline’ state, which for each child will
be established at enrolment, prior to any exacerbations.
This assessment consists of a combination of symptoms
(daily cough (yes/no), cough quality (wet/dry/none) and
cough score [31] averaged over two consecutive days)
and signs (sputum colour (if any present) using a colour
chart card (BronkoTest Ltd, London, UK), crackles on
chest auscultation). Children will be reviewed on days 7
and 14 and at resolution of the exacerbation. The ex-
acerbation is considered ‘resolved’ when symptoms and
signs are the same as ‘baseline’ state. Post exacerbation,
the children will be followed-up and clinically evaluated
every three months for 18 months or until their next
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mined by the number of days from ‘resolution of current
exacerbation’ to beginning of the next exacerbation.
Randomisation, allocation and blinding
Upon enrolment, the child is assigned to the next
unique number on the appropriate stratified list. The al-
location will be performed by the trial pharmacist at the
Royal Children’s Hospital in Brisbane. Randomisation is
stratified by site (Brisbane, Perth, Darwin, Melbourne,
Auckland), age (≤ 5 or > 5 years) and underlying aeti-
ology (idiopathic/post-pneumonia or all other causes).
The randomisation sequence was computer generated
and used permuted blocks. The allocation sequence is
concealed at all times throughout the study. The com-
puter generated allocation sequence was prepared by a
statistician external to the study team.
The placebo medications, specifically manufactured by
the Institute of Drug Technology Australia Limited
(Melbourne, Victoria), have a similar taste and colour to
their respective antibiotics. Both active medications
(amoxicillin-clavulanic acid and azithromycin) are
repackaged by the Institute of Drug Technology. Thus
both the amoxicillin-clavulanic acid and azithromycin
and their respective placebos are in identical opaque
bottles. For both types of trial medications, equal
volumes of water are added using a syringe and needle
by punching the seal. Adherence will be assessed by par-
ent report and return of empty bottles.
Data collection
All data will be recorded on standardised forms. On en-
rolment, demographic information (age, gender, ethnicity,
household size, and so on), birth history, breast feeding
history, prior illness and in utero and household smoke
exposure will be recorded, and a physical examination
will be performed by a study physician. The primary and
secondary outcome measures (see below) are collected at
the time points specified above. Serious and non-serious
adverse effects (nausea, vomiting, diarrhoea, rash) will
also be documented and monitored. Safety exit points are
discussed in End points below.
Specimen collection
At enrolment (baseline), all children will have a deep
nasal swab (NS) specimen collected. In a subset, add-
itional specimens will be collected at baseline and during
exacerbations depending on feasibility (some children
are unable to attend the study centre at the onset of the
exacerbation) and willingness of parents to allow add-
itional venipuncture. These specimens are:
 A deep NS specimen for respiratory viruses,
respiratory bacterial pathogens (with antibioticsusceptibility testing) and other potentially
important respiratory pathogens (M. pneumoniae,
Chlamydia spp) at baseline and at the beginning and
resolution of an exacerbation. The technique used is
identical to previous studies [34-36] where the
specimens were described as nasopharyngeal swabs.
The NSs are handled as per our research laboratory
protocol (see below).
 Bloods at baseline and at the beginning and end of
each exacerbation for C-reactive protein (CRP),
neutrophilic marker of inflammation (IL-6) [37],
serum amyloid A (SAA) [33,38] and markers of viral
infection (interferon gamma-inducible protein 10
(IP-10) and IL-10).
 Sputum at baseline and at the beginning and end of
each exacerbation (when possible) for lower airway
microbiology and antibiotic sensitivity.
Further description of scores and laboratory methods
Cough score
The verbal categorical descriptive score is a validated
daily diary score of cough rated on a six-point scale
(0 = no cough to 5 = severe cough and cannot perform
activities) with increasing scores reflecting greater inter-
ference with usual activities. This rating was validated
against an objective cough meter measure [31] and
changes in cough scores have been shown to reflect
changes in objective cough counts [39].
Parent Chronic Cough Quality of Life score
The Parent Chronic Cough Quality of Life (PC-QOL) is
a 27-item questionnaire designed to assess the level of
frequency of feelings (15 items) and worry (12 items)
related to their child’s cough. It uses a seven-point
Likert-type scale with higher scores reflecting less fre-
quency and fewer worry concerns (that is, greater QOL)
[40,41]. The minimal important difference is 0.62 deter-
mined by the distribution method and 0.9 determined
by the anchor method [42].
Bacteriology of nasal swabs
Oropharyngeal sampling under estimates Streptococcus
pneumoniae carriage by approximately 50% when com-
pared with NS [43]. Thus, NS are the preferred method
when evaluating the presence of antibiotic-resistant bac-
teria. Culturing, identifying and, when appropriate, sero-
typing common respiratory bacteria are established
techniques at our research laboratory [36,44]. Swabs are
stored in skim milk tryptone glucose glycerol broth
medium at −80°C before being batch processed for typical
respiratory bacterial pathogens, notably Haemophilus
influenzae (including strains of non-typeable H. influenzae),
Moraxella catarrhalis and S. pneumoniae. Batches of
swabs are thawed and 10-μL aliquots cultured overnight
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of S. pneumoniae, H. influenzae and M. catarrhalis is
recorded and confirmed by standard techniques [36,45].
Four isolates each of S. pneumoniae and H. influenzae
and two isolates of M. catarrhalis per positive swab
are tested for antimicrobial resistance and stored
[36,45]. S. pneumoniae isolates are serotyped using
the Quellung method (antisera from Statens Serum
Institute, Copenhagen,Denmark).
In addition to routine susceptibility testing using the
calibrated dichotomous susceptibility disc diffusion
method, azithromycin minimum inhibitory concentration
(MIC) will be determined by Etests (AB Biodisk, Solna,
Sweden) if the azithromycin disc annulus is <6 mm. For S.
pneumoniae, the penicillin MIC is determined for penicil-
lin non-susceptible isolates (oxacillin and/or penicillin disc
annulus < 6 mm) and for H. influenzae, the ampicillin
MIC is determined for isolates if the ampicillin disc annu-
lus is < 6 mm. Interpretive criteria (Clinical and Laboratory
Standards Institute breakpoints) used for S. pneumoniae
are penicillin non-susceptible MIC>0.12 μg/mL, azithro-
mycin resistance MIC≥ 2 μg/mL; and for H. influenzae,
ampicillin resistance MIC≥ 4 μg/mL, azithromycin resist-
ance MIC>4 μg/mL. A nitrocephin-based test will iden-
tify beta-lactamase activity in H. influenzae and M.
catarrhalis isolates.
Assessment for viruses and atypical bacteria
We will use our previous methods [46,47]. Nucleic acids
will be extracted from the media using the High Pure
Viral Nucleic Acid kit (Roche Diagnostics, Sydney, New
South Wales, Australia), according to the manufacturer’s
instructions. Real-time polymerase chain reaction assays
will be used to detect respiratory syncytial viruses (A and
B), adenoviruses, influenza viruses (A and B), parainflu-
enza, human metapneumovirus, human coronaviruses
(OC43, HK1, 229E, NL63), enteroviruses, rhinoviruses
(and subtypes [48]) and the more recently described
human viruses (human bocavirus 1, parechoviruses,
human polyomaviruses K1 and WU) and M. pneumoniae
and Chlamydia species [49].
Blood markers
Serum CRP (threshold 5 mg/L) are standard tests that
will be analysed locally (diagnostic laboratory of each
participating centre). SAA, IL-6 (threshold < 3 pg/mL),
IL-10 (threshold < 0.5 pg/mL) and IP-10 (threshold
2.8 pg/mL) will be performed using ELISA commercial
kits (R&D Systems, Minneapolis, MN, USA) at our
research laboratory.
Spirometry
Spirometry (in children aged ≥ 5 years) will be performed
using American Thoracic Society criteria and the FEV1%predicted recorded. We elected not to use oscillatory
measures as we found no difference in airway resistance
between steady and exacerbation states [33]. Thus we
will use conventional spirometry although we do not ex-
pect to detect significant differences.
End points
Participation is complete when the child’s clinical state
returns to baseline and the ‘time to next exacerbation’
has been obtained. Other exit points are if the child is
clinically worse prior to day 14 or intolerance to the trial
medications requiring withdrawal from the study (as
determined by the treating clinician).
Outcome measures
Primary outcome
The primary outcome is the proportion of children
whose exacerbations have resolved by day 14. Exacerba-
tions will be considered resolved when symptoms and
signs are the same as the baseline state. Children who
are withdrawn from the study or receive additional anti-
biotic treatment will be categorised as non-resolved.
Secondary clinical outcomes
The main secondary outcome is the PC-QOL score.
Other outcomes are the time to next exacerbation; re-
quirement for hospitalisation; duration of exacerbation
(persistence of symptoms till ‘return to baseline state’)
and FEV1% predicted.
Secondary laboratory outcomes
Serum markers (CRP, SAA, IL-6, IL-10, IP-10) and data
on viruses and respiratory bacterial pathogens, including
antibiotic susceptibility patterns to penicillin and azi-
thromycin, will be the secondary laboratory outcomes.
Sample size
We plan to enrol 189 children (63 per arm), providing
84% power (α= 0.0245, two-sided) to detect a halving of
the number of children in the active arm achieving reso-
lution by day 14 (that is, azithromycin or amoxicillin-
clavulanic acid: 60% resolved by day 14, compared with
placebo: 30% resolved). This is a conservative estimate
when compared with our prospective data of persistent
symptoms in 24% of children based on the same diary
card [50]. As the primary outcome will be obtained in all
enrolled children, a drop-out has not been factored in
for the intention-to-treat analysis. With 20% drop-out
rate, data from 153 children (51 per arm) for ‘per proto-
col’ analysis provides a study power of 75%. Both treat-
ment arms are compared with the same placebo arm.
While the maximum efficiency is attained by allocating
more children to the placebo arm (that is, using an allo-
cation ratio of 1:1:√2), we chose to use a 1:1:1 allocation
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in respiratory centres.
In the main secondary outcome (PC-QOL), based on a
between-group difference of 0.9 (minimum important
difference [42]) (SD 0.9), our sample size provides power
of 100% (α= 0.05) for data from at least 147 children
(that is, assuming at least 80% retention of the 189 chil-
dren enrolled). For secondary aim 2 (exploring factors
that predict response to antibiotics), we will be examin-
ing eight main factors and thus a sample size of 147
exceeds the recommended minimum (n= 10 per factor)
[51]. The eight factors are smoking, age, underlying aeti-
ology, detection of virus (any versus none, then single
versus multiple viruses), presence of azithromycin resist-
ance and blood markers (IL-6, IL-10, IP-10 levels).
Statistical analysis and reporting
Data will be reported and presented in accordance with
the updated CONSORT criteria [52]. Children will be
analysed according to allocation status (regardless of
subsequent management). An interim analysis is planned
and a data safety and monitoring committee will determine
if the study should be ceased should superiority of any anti-
biotic be identified after 50% of sample size is achieved.
For our primary aim, the main effects of the interven-
tions will be determined by comparing the primary
outcome (resolution of exacerbation) between groups
((azithromycin versus placebo) and (amoxicillin-clavula-
nic acid versus placebo)). Children who exit the study as
clinically worse or drop-outs prior to the end point will
be considered non-resolved. Those who exit the study as
‘returned to baseline’ will be considered resolved. Odds
ratios will be calculated and, if appropriate, number
needed to treat (for benefit) will be expressed. Tests of a
treatment arm versus placebo at the end of the study for
the primary outcome will be performed at the 2.45% sig-
nificance level to account for spending some alpha at
the interim analysis. Per protocol analysis will be an a
priori secondary analysis.
For secondary outcomes and aims
For clinical secondary outcomes (secondary aim 1), t-tests
or Mann–Whitney will be used for continuous variables
(according to normality of data distribution). A Kaplan-
Meier curve will be constructed for each group for ‘time
to resolution’ and ‘time to next exacerbation’ as done
previously [53]. For secondary aim 2 (factors that predict
response to antibiotics), univariate analysis will be used to
examine the biological factors listed above. Factors that
have a P-value < 0.2 will be included in a logistic regression
model. Potential interactions (for example, virus with bac-
teria) will be examined in the model. Descriptive data will
be used for secondary aim 3 (point prevalence of respira-
tory pathogens).Data safety monitoring committee
A data safety monitoring committee has been estab-
lished and has met prior to commencement of this
study. It was determined that, when 50% of the sample
size has been achieved, the stopping rules are as detailed
below.
 If superiority between each antibiotic arm and the
placebo arm is shown at significance level of 0.001,
the study will cease. If superiority of only one
antibiotic is shown, we will continue recruiting
children to the other antibiotic arm and to the
placebo arm but not to the superior antibiotic arm.
 If the serious adverse events (related to the
medications) in each antibiotic arm outnumber the
adverse events in the placebo arm at significance
level of 0.01 or less, the study will cease. If increased
adverse events of only one antibiotic is shown, we
will continue recruiting children to the other
antibiotic arm and to the placebo arm but not to the
antibiotic arm related with increased adverse events.
However, the study is not powered to detect
between-group differences in total adverse events.
Ethics approval
The protocol has received ethical approval from the re-
spective Human Research Ethics Committees of all the
participating institutions (Darwin: Department of Health
and Families and Menzies School of Health Research;
Brisbane: Children’s Health Services (Royal Children’s
Hospital) and University of Queensland; Perth: Princess
Margaret Hospital; Melbourne: Royal Children’s Hos-
pital; Auckland: Northern Ethics Committee, Ministry of
Health and Starship Children’s Health local ethics com-
mittee). The study is being conducted under Australia’s
Therapeutic Goods Administration Clinical Trial Notifi-
cation scheme.
Discussion
Despite the considerable global burden, bronchiectasis ser-
vices receive disproportionately fewer allocated resources
(clinical and research) when compared with other chronic
respiratory diseases [3,54,55]. The marked paucity of RCTs
[21,55] is reflected in the existence of only a single (small)
published placebo-controlled RCT in children with bron-
chiectasis [21,56]. That study described a reduction in
sputum purulence and airway hyper-responsiveness in
children receiving roxithromycin (n= 13) [57]. There are
no RCTs on the management of bronchiectasis exacer-
bations in children [58]. Almost all current recommen-
dations are based on CF management [21,28]. Such
extrapolation can, on occasions, be detrimental for those
with non-CF bronchiectasis. For example, a large RCT
found that deoxyribonuclease (efficacious for CF)
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with bronchiectasis [59] despite prior case reports advo-
cating its use [60].
The importance of exacerbations in most chronic re-
spiratory diseases is generally accepted. Unfortunately,
data on triggers, definitions and effective treatment of
bronchiectasis exacerbations in both children and adults
are scarce [56,61,62]. Although viral triggers of acute
exacerbations are well described in asthma [46] and COPD
[63,64], no such data exist for bronchiectasis. Whether
other potential respiratory pathogens (M. pneumoniae and
Chlamydia species) trigger exacerbations has never been
examined. Our retrospective study found that 34% of
exacerbations were preceded by a viral-like illness [29].
Thus, for the first time in this population, we will deter-
mine the nature and diversity of respiratory viruses M.
pneumoniae and Chlamydia species associated with bron-
chiectasis exacerbations.
Our study addresses a large knowledge gap in an
under-researched area [55]. If the intervention is suc-
cessful, it would lead to improved short-term (and pos-
sibly long-term) health benefits. Conclusive results
would produce changes to evidence-based standard
treatment guidelines.
The rationale for our chosen outcome measures and
timeframe
In our retrospective data of 115 respiratory exacerba-
tions [29], we found that 35% of exacerbations failed to
respond to oral antibiotic therapy (duration could not be
determined) and required hospital admission. In our
prospective cohort of 69 children followed for 900 child-
months (156 exacerbations), 36 exacerbations (23%)
were treated with intravenous antibiotics following per-
sistence of symptoms, that is, non-resolution of the ex-
acerbation episode. Generally, hospitalisation began
three to five weeks following the initiation of oral anti-
biotics and ‘return to baseline’ occurred within two
weeks of hospitalisation. Based on our data that 24% of
otherwise well children in the community still have a
cough associated with a viral infection at day 14 [50], we
chose day 14 as the time point for this RCT. We also
asked parents and clinicians about their willingness to
use placebo for a period of time; 14 days was the limit
with a safety exit point at day 7.
Adult bronchiectasis studies show that QOL measures,
particularly cough-specific QOL, are valid and important
outcome measures [62,65]. Likewise, we have shown the
utility of a paediatric chronic cough QOL (the PC-QOL)
score in children with bronchiectasis [66].
In summary, our double-blind, double-dummy RCT
that examines the superiority of azithromycin and
amoxicillin-clavulanic acid (compared with placebo) for
exacerbations of bronchiectasis in children has thepotential to have both short-term gains and a long-term
benefit for reducing the morbidity of bronchiectasis.
Trial status
We commenced recruitment in Darwin in mid-March
2012, Brisbane in June 2012 and the other sites are
expected to commence in August 2012. We commenced
randomisation in late May 2012.
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